Form 4: ALUMIS Grants Stock Options to Chief Business Officer

ALUMIS Inc. granted 190,875 stock options to Chief Business & Strategy Officer Roy C. Hardiman with an exercise price of $26.31.

Summary

• Roy C. Hardiman, Chief Business & Strategy Officer of ALUMIS INC. (ALMS), was granted stock options.
• The transaction for the option grant occurred on January 26, 2026.
• Mr. Hardiman acquired 190,875 stock options.
• The exercise price for these options is $26.31 per share.
• The options have an expiration date of January 25, 2036.
• The vesting schedule dictates that 25% of the shares underlying the option vest on January 26, 2027.
• The remaining shares will vest in equal monthly installments thereafter over the following 36 months, subject to Mr. Hardiman's continuous service to the Issuer.

Sentiment

Score: 6

Explanation: The filing reports a standard executive compensation event, which is generally viewed as neutral to slightly positive as it aligns executive interests with shareholders, without indicating any immediate operational or financial changes.

Positives

• The granting of stock options aligns the Chief Business & Strategy Officer's interests with those of shareholders, incentivizing long-term company performance.
• This is a standard component of executive compensation packages, indicating a commitment to retaining key talent within the company.

Future Outlook

The vesting schedule, extending over 36 months after the initial 25% vest, indicates a long-term incentive structure designed to retain the Chief Business & Strategy Officer and align his future performance with the company's success, contingent on his continuous service.

Industry Context

The granting of stock options to key executives is a common practice across various industries, particularly in technology and biotechnology sectors like ALUMIS, to attract, retain, and motivate senior leadership by linking their compensation to the company's stock performance.

Comparison to Industry Standards

• The structure of this option grant, including a multi-year vesting schedule, is consistent with typical executive compensation practices observed in publicly traded companies, especially those in the biotechnology or pharmaceutical sectors.
• Companies like Amgen, Gilead Sciences, and Biogen frequently utilize similar long-term equity incentives to align executive interests with shareholder value creation.

Stakeholder Impact

• Shareholders: Interests are aligned with the Chief Business & Strategy Officer through equity incentives, potentially leading to improved long-term performance.
• Employees: May view this as a positive sign of executive commitment and stability, potentially boosting morale.

Next Steps

• Continued vesting of the granted stock options over the next 36 months, subject to the reporting person's continuous service to the Issuer.

Key Dates

Keywords

ALUMIS, ALMS, Stock Option, Executive Compensation, Roy C. Hardiman, Form 4